Rise of High-Priced ATMPs Fuels Demand for More Flexible and Equitable HTA Mechanisms
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Over the past few years, the growing influx of advanced therapy medicinal products (ATMPs) has delivered substantial advances in terms of treatment options and even cures for diseases that previously lacked effective therapies. However, these ATMPS often carry substantial development or production costs, and the need for the pharma industry to recover these costs can severely restrict their adoption by health authorities around the world. As such, demand has risen for new, more flexible, more equitable health technology assessment (HTA) mechanisms, which would allow ATMPs to be brought to a much wider patient population.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Product Type reports